Takeda Pharmaceutical Company Ltd

🇸🇪Sweden

Country: 🇸🇪Sweden

Ownership: -

Established: 1925-01-01

Employees: -

Market Cap: $47.5B

Website: http://www.takeda.co.jp/

Clinical Trials

A Study in Relapsed and/or Refractory Multiple Myeloma Patients Treated With Ixazomib Plus Lenalidomide and Dexamethasone

Completed

Conditions: Relapsed and/or Refractory Multiple Myeloma

Interventions: Drug: Ixazomib
Drug: Lenalidomide
Drug: Dexamethasone

First Posted Date: 2018-02-14

Last Posted Date: 2023-12-07

Lead Sponsor: Takeda

Target Recruit Count: 295

Registration Number: NCT03433001

Locations: 🇯🇵
Takeda Selected Site, Tokyo, Japan

Lot-to-lot Consistency of 3 Lots of Tetravalent Dengue Vaccine (TDV) in Non-endemic Country(Ies) for Dengue

Phase 3

Completed

Conditions: Dengue Fever

Interventions: Biological: TAK-003
Biological: Placebo

First Posted Date: 2018-02-06

Last Posted Date: 2020-10-20

Lead Sponsor: Takeda

Target Recruit Count: 923

Registration Number: NCT03423173

Locations: 🇺🇸
Synexus Limited - Columbus, Columbus, Ohio, United States
🇺🇸
Optimal Research, Rockville, Maryland, United States
🇺🇸
Anaheim Clinical Trials, LLC, Anaheim, California, United States

and more 7 locations

A Phase 1 Drug-Drug Interaction Study Between Brigatinib and the CYP3A Substrate, Midazolam, in Participants With ALK-Positive or ROS1-Positive Solid Tumors

Phase 1

Completed

Conditions: Carcinoma, Advanced ALK+ or ROS1+Non-Small-Cell Lung, Neoplasm, Advanced ALK+ or ROS1+Solid Tumors

Interventions: Drug: Midazolam
Drug: Brigatinib

First Posted Date: 2018-02-05

Last Posted Date: 2023-01-27

Lead Sponsor: Takeda

Target Recruit Count: 24

Registration Number: NCT03420742

Locations: 🇫🇷
Hopital de la Timone, Marseille, Provence Alpes COTE D'azur, France
🇮🇹
Policlinico Sant'Orsola Malpighi, Bologna, Italy
🇮🇹
Ospedale San Raffaele, Milano, Italy

and more 11 locations

A Study to Evaluate the Efficacy and Safety of Ixazomib in Combination With Lenalidomide and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma Initially Treated With an Injection of Proteasome Inhibitor-Based Therapy

Phase 4

Completed

Conditions: Relapsed and/or Refractory Multiple Myeloma

Interventions: Drug: Ixazomib
Drug: Bortezomib
Drug: Carfilzomib
Drug: Lenalidomide
Drug: Dexamethasone

First Posted Date: 2018-01-31

Last Posted Date: 2022-09-27

Lead Sponsor: Takeda

Target Recruit Count: 45

Registration Number: NCT03416374

Locations: 🇯🇵
Juntendo University Hospital, Bunkyo-ku, Tokyo, Japan
🇯🇵
Kyorin University Hospital, Mitaka, Tokyo, Japan
🇯🇵
Nippon Medical School Hospital, Bunkyo-ku, Tokyo, Japan

and more 20 locations

Phase 2 Study of Brigatinib in Japanese Participants With Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small Cell Lung Cancer (NSCLC)

Phase 2

Completed

Conditions: ALK-positive Advanced NSCLC

Interventions: Drug: Brigatinib

First Posted Date: 2018-01-25

Last Posted Date: 2024-05-08

Lead Sponsor: Takeda

Target Recruit Count: 104

Registration Number: NCT03410108

Locations: 🇯🇵
Aichi Cancer Center Hospital, Nagoya, Aichi, Japan
🇯🇵
National Cancer Center Hospital East, Kashiwa, Chiba, Japan
🇯🇵
Kurume University Hospital, Kurume, Fukuoka, Japan

and more 30 locations

Assessment of Immune Activation and Tolerance in Celiac Disease During Gluten Challenge

Not Applicable

Completed

Conditions: Celiac Disease

Interventions: Dietary Supplement: Gluten

First Posted Date: 2018-01-24

Last Posted Date: 2022-05-24

Lead Sponsor: Takeda

Target Recruit Count: 16

Registration Number: NCT03409796

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

A Study to Assess the Effectiveness and Safety of Treatment With Vedolizumab in Adult Participants With Ulcerative Colitis (UC) or Crohn's Disease (CD) in Real Life

Terminated

Conditions: Colitis, Ulcerative
Crohn Disease
Inflammatory Bowel Diseases

First Posted Date: 2017-12-19

Last Posted Date: 2020-10-14

Lead Sponsor: Takeda

Target Recruit Count: 29

Registration Number: NCT03378388

Locations: 🇫🇷
Centre Hospitalier Cote Basque, BAYONNE Cedex, France
🇫🇷
Ch de Blois, Blois Cedex, France
🇫🇷
Clinique du palais, Grasse, France

and more 10 locations

A Phase 4 Post-marketing Study of Intramuscular Injections of BLB-750 in Healthy Adult Subjects

Phase 4

Completed

Conditions: Pandemic Influenza Prevention

Interventions: Biological: BLB-750 Vaccine (Qinghai RG strain)

First Posted Date: 2017-12-12

Last Posted Date: 2019-07-29

Lead Sponsor: Takeda

Target Recruit Count: 55

Registration Number: NCT03370289

Locations: 🇯🇵
Sekino Rinsho Yakuri Clinic, Toshima-ku, Tokyo, Japan

Safety, Immunogenicity, and Dose Ranging Study of Inactivated Zika Virus Vaccine in Healthy Participants

Phase 1

Completed

Conditions: Virus, Zika
Healthy Participants
Zika Virus Disease
Flavivirus Infections

Interventions: Drug: Placebo
Biological: PIZV

First Posted Date: 2017-11-17

Last Posted Date: 2022-02-11

Lead Sponsor: Takeda

Target Recruit Count: 271

Registration Number: NCT03343626

Locations: 🇺🇸
Johnson County Clin-Trials, Lenexa, Kansas, United States
🇵🇷
Ponce Medical School Foundation, Santurce, Puerto Rico
🇵🇷
Puerto Rico Clinical and Translational Research Consortium, San Juan, Puerto Rico

and more 6 locations

Immunogenicity and Safety of Tetravalent Dengue Vaccine (TDV) Administered With a Yellow Fever Vaccine in Adults

Phase 3

Completed

Conditions: Dengue

Interventions: Biological: YF-17D
Biological: TDV
Drug: Placebo

First Posted Date: 2017-11-17

Last Posted Date: 2020-10-08

Lead Sponsor: Takeda

Target Recruit Count: 900

Registration Number: NCT03342898

Locations: 🇺🇸
Coastal Clinical Research Inc, Mobile, Alabama, United States
🇺🇸
Rapid Medical Research Inc, Cleveland, Ohio, United States
🇺🇸
Empire Clinical Research, Pomona, California, United States

and more 7 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy